Introduction {#Sec1}
============

Esophageal cancer is a highly lethal malignancy with a 5-year survival rate of approximately 15% \[[@CR1]\]. Thus, the management of patients with esophageal cancer is challenging and requires a multimodal approach. Suboptimal results have been reported for post-operative adjuvant chemotherapy \[[@CR2]\], radiotherapy \[[@CR3]\] and concurrent chemoradiotherapy \[[@CR4]\]; thus, interest in neoadjuvant treatment has recently increased. In particular, Sjoquist *et al*. reported that, among patients with resectable esophageal cancer, those who received neoadjuvant chemoradiotherapy showed a significant survival benefit compared to patients who received surgical treatment alone \[[@CR5]\]. However, the incidence of esophageal cancer and squamous cell carcinoma is known to increase with age. The incidence of cancer peaks in the seventh decade of human life \[[@CR6]\]. Thus, even if resection is possible, surgical treatment cannot be performed in some patients because of their general condition or accompanying comorbidities at the time of diagnosis. In this report, we describe the case of a patient with esophageal cancer who could not undergo surgical treatment because he also had chronic obstructive pulmonary disease (COPD). We successfully treated the patient with endoscopic submucosal dissection (ESD) after concurrent chemoradiotherapy. Our description of the case is accompanied by a discussion of relevant literature.

Case presentation {#Sec2}
=================

An 82-year-old Korean man was admitted to our hospital with a chief complaint of intermittent odynophagia of approximately 3 months' duration. The patient did not have a history of alcohol intake. He was a current smoker with a smoking history of 120 pack-years (2 packs daily for 60 years). He had been taking medication and using an inhaler for approximately 20 years to treat his COPD. A pulmonary function test (performed approximately 2 months prior to his presentation) revealed poor respiratory function with a forced expiratory volume in 1 second of approximately 45%.

An endoscopic examination showed a broad, ulcerative lesion at 33cm to 38cm from the incisor that spanned more than three-fourths of the esophageal lumen circumference (Figures [1](#Fig1){ref-type="fig"}A and [1](#Fig1){ref-type="fig"}B). The biopsy findings indicated moderately differentiated squamous cell carcinoma. Endoscopic ultrasonography (EUS) revealed a blurring and thickening of the third layer (submucosal layer). However, the fourth layer (proper muscle layer) was spared. In addition, we observed three malignant lymph nodes \>10mm that were round in shape, had smooth features and exhibited hypoechogenicity. They were located 27cm, 28cm and 42cm from the incisor (Figures [2](#Fig2){ref-type="fig"}A, [2](#Fig2){ref-type="fig"}B, [2](#Fig2){ref-type="fig"}C and [2](#Fig2){ref-type="fig"}D). However, we did not find any metastases on a computed tomography (CT) scan or a positron emission tomography (PET)-CT scan.Figure 1**Endoscopic examination.** Esophageal cancer was observed at the middle to distal esophagus. It spanned more than three-fourths of the luminal circumference. **(A)** White light endoscopy. **(B)** Chemoendoscopy with iodine staining. After chemoradiotherapy, the lesion size decreased to approximately half of the circumference of the esophageal lumen. **(C)** White light endoscopy. **(D)** Chemoendoscopy with iodine staining.Figure 2**Endoscopic ultrasonography findings. (A)** Blurring and thickening of the submucosal layer were observed, but the proper muscle layer was spared. Three enlarged regional lymph nodes (\>10mm) were observed at 42cm **(B)**, 28cm **(C)** and 27cm **(D)** from the incisor.

The patient was clinically diagnosed with T1b N2 M0 G2, stage IIIA cancer (according to the American Joint Committee on Cancer (AJCC) staging system \[[@CR7]\]) and treated with concurrent chemoradiotherapy. His chemotherapy was 5-fluorouracil plus cisplatin, and his radiotherapy of 50 Gy was delivered in 25 fractions. In a follow-up endoscopic examination performed after 5 weeks of chemoradiotherapy, we found that the lesion had decreased in size to approximately one-half the circumference of the esophageal lumen. The ulceration also demonstrated a pattern of improvement upon macroscopic observation (Figures [1](#Fig1){ref-type="fig"}C and [1](#Fig1){ref-type="fig"}D). In addition, the previously observed malignant lymph nodes were not seen on follow-up EUS, CT and PET-CT scans. After chemoradiotherapy, the patient showed a sufficient response to be clinically down-staged to T1a/T1b N0 M0 G2, stage IA (according to the AJCC staging system \[[@CR7]\]). Though additional surgical treatment was considered with the goal of a complete cure, we acquired informed consent for ESD instead after explaining to the patient and his guardian the high post-operative risk posed by his class IV condition (American Society of Anesthesiologists classification), which was due to his poor pulmonary function (Figures [3](#Fig3){ref-type="fig"}A, [3](#Fig3){ref-type="fig"}B and [3](#Fig3){ref-type="fig"}C). A specimen measuring approximately 5×4.8cm in size was acquired through an *en bloc* resection (Figure [4](#Fig4){ref-type="fig"}A). Using the specimen, we confirmed the diagnosis of moderately differentiated squamous cell carcinoma with focal observation of submucosal invasion (sm1, shallower one-third of the submucosa) (Figure [4](#Fig4){ref-type="fig"}B).

After ESD, the patient developed an iatrogenic ulcer covering nearly the total circumference of the esophageal lumen. We therefore predicted a high possibility of secondary luminal stenotic change in the future. Consequently, we administered endoscopic triamcinolone injections (ETIs) on the third, seventh and tenth days after ESD. Follow-up endoscopic examinations were performed at 1 week and at 1, 3 and 6 months after ETI (Figure [5](#Fig5){ref-type="fig"}A, [5](#Fig5){ref-type="fig"}B, [5](#Fig5){ref-type="fig"}C and [5](#Fig5){ref-type="fig"}D). They showed neither luminal stenosis nor local recurrence. In addition, esophagography and esophageal manometry tests performed 3 months after ETI did not yield findings of particular interest.Figure 3**Endoscopic submucosal dissection. (A)** Pre-cutting was performed along the outer border of the lesion. **(B)** Submucosal dissection was performed. **(C)** A large iatrogenic ulcer was observed after the procedure.Figure 4**Pathologic findings. (A)** Macroscopic finding of a specimen approximately 5cm in size after *en bloc* resection. **(B)** Squamous cell carcinoma with focal submucosal invasion.Figure 5**Endoscopic findings after endoscopic triamcinolone injection. (A)** 1 week post-injection. **(B)** 1 month post-injection. **(C)** 3 months post-injection. **(D)** 6 months post-injection.

The patient has been followed on an outpatient basis and has not displayed abnormal symptoms such as dysphagia or regurgitation. Currently, neither local nor distant recurrences of esophageal cancer have been observed after 36 months.

The study protocol was approved by Daegu Fatima Hospital Ethics Committee. The patient gave us written informed consent before the procedure.

Discussion {#Sec3}
==========

As is the case with the majority of gastrointestinal tract malignancies, esophageal cancer has a potentially curative therapy consisting of surgical treatment (esophagectomy with therapeutic lymphadenectomy). However, with recent reports of survival benefits \[[@CR8]\] and complete resection rate increases in patients receiving neoadjuvant chemoradiotherapy \[[@CR9]\], that approach has received attention as a standard treatment for locally advanced esophageal cancer \[[@CR10]\]. Our patient had stage IIIA disease at the time of initial diagnosis, but restaging after neoadjuvant chemoradiotherapy showed a significant down-staging effect to stage IA disease.

It is well known that the surgical risk of esophagectomy varies by clinical characteristics such as age and comorbidities. Finlayson *et al*. reported that the 30-day mortality of esophagectomy was 10.7% among patients in their 60s, but that it increased to 20% among patients in their 80s \[[@CR11]\]. Moreover, it is well known that the presence and severity of comorbidities affect disease prognosis as well as surgical outcome. Our patient was 82 years old and exhibited poor pulmonary function. Therefore, we could not perform surgical treatment, despite the fact that his esophageal cancer remained in a resectable state, and we performed ESD instead.

In actuality, endoscopic resection should be avoided in patients with esophageal cancer with submucosal invasion, because there is a substantial risk of regional lymph node metastasis. Ancona *et al*. reported confirmation of lymph node metastasis in approximately 28% of esophageal cancers with submucosal layer invasion \[[@CR12]\]. In our patient, EUS performed during diagnosis showed invasion of the submucosal layer and three regional metastatic nodes. However, EUS performed after neoadjuvant chemoradiotherapy showed an absence of these regional lymph nodes, and ESD was planned only then. Clearly, ESD would not have been planned as a follow-up treatment if, in the initial diagnosis, there were EUS or CT findings that the lesion had invaded the muscularis propria or adventitia or any adjacent structures. Furthermore, we could not directly confirm T stage improvement by EUS prior to ESD, because radiation-induced inflammation of the esophageal wall and residual disease cannot be differentiated easily on EUS scans after neoadjuvant chemoradiotherapy \[[@CR13]\]. However, at the time of initial diagnosis, EUS showed only submucosal invasion of the lesion. In addition, as regional lymph nodes showed improvement following neoadjuvant chemoradiotherapy, we indirectly predicted that the T staging of the lesion would not progress beyond T1b. We therefore thoroughly explained the process to the patient and his guardians and acquired informed consent to proceed with ESD.

After neoadjuvant chemoradiotherapy, the lesion area decreased significantly. However, as we performed ESD with a sufficient lateral safety margin, an iatrogenic ulcer that occupied the majority of the short axis of the esophageal lumen unavoidably developed post-operatively. We therefore performed ETI to prevent a secondary luminal stricture. The ETI was performed following a protocol described by Hashimoto *et al*. \[[@CR14]\]. In accordance with that protocol, triamcinolone acetonide (10mg/ml) was placed in a 1-ml syringe. Then, a 25-gauge, 4mm needle (FINEMEDIX, Daegu, South Korea) was used to inject the triamcinolone in increments of 0.2ml (2mg) at 1cm intervals along the long axis and short axis of the ulcer base \[[@CR14]\]. No luminal stricture was observed in a follow-up endoscopic examination performed after triamcinolone injection.

The patient remained in a disease-free state without local or distant recurrence 36 months after ESD. This is considered to be due to the fact that the cancer differentiation was not "poor" and the regional lymph node metastases resolved as a result of neoadjuvant chemoradiotherapy. The primary cancer site was also successfully treated to R0 resection through ESD and now shows a good prognosis.

Conclusions {#Sec4}
===========

On the basis of our experience in this case, we think that ESD treatment can be considered in patients with resectable esophageal cancer if surgery poses a high risk because of comorbidities or the age of the patient and if there is a good response to neoadjuvant chemoradiotherapy. Furthermore, with respect to the large iatrogenic ulcer that occurred after ESD in our patient, we found that triamcinolone injection via endoscopy was effective in preventing luminal stricture.

Consent {#Sec5}
=======

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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